Elevai Labs, Inc. (ELAB) shares surged 50% after the company signed an exclusive, worldwide manufacturing and processing technology licensing agreement with INmune Bio, Inc.
ELAB is trading on the Nasdaq at $2.57, up 50.42% or $0.86 per share. It has traded between $1.50 and $4.24 in the past 52-week period.
The agreement grants Elevai an exclusive license to use the "EMx" technology for the development and commercialization of licensed topical cosmetic products sold in the medical aesthetics skincare market.
The technology allows for efficient production of human umbilical cord-derived mesenchymal stromal cells (hucMSCs) at a lower cost than purchasing hucMSCs outright.
Elevai will pay the license's initial deposit in two equal installments spread out for six months, per the agreement.
They also agree to pay a final tech transfer fee within two years of the agreement's execution. Elevai will be obliged to pay a small royalty on the sales of licensed topical cosmetic products made with the "EMx" technology as additional consideration under the terms of the agreement.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.